Home
Categories
EXPLORE
True Crime
Comedy
Business
Society & Culture
Sports
History
Fiction
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/a0/f3/b7/a0f3b787-bac2-8259-9747-c7e3d53fa9ca/mza_8952235022428513734.jpg/600x600bb.jpg
Few & Far Between: How Biotech Gets Built
Chris O'Brien
35 episodes
1 day ago
Welcome to Few & Far Between! Chris O'Brien, CEO of Biorasi, is your host for fascinating conversations - from clinical research and policymakers to biotech innovators and industry leaders.
Show more...
Life Sciences
Health & Fitness,
Mental Health,
Medicine,
Science
RSS
All content for Few & Far Between: How Biotech Gets Built is the property of Chris O'Brien and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Welcome to Few & Far Between! Chris O'Brien, CEO of Biorasi, is your host for fascinating conversations - from clinical research and policymakers to biotech innovators and industry leaders.
Show more...
Life Sciences
Health & Fitness,
Mental Health,
Medicine,
Science
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/a0/f3/b7/a0f3b787-bac2-8259-9747-c7e3d53fa9ca/mza_8952235022428513734.jpg/600x600bb.jpg
Video Episode 64 - Professor Justin Stebbing
Few & Far Between: How Biotech Gets Built
47 minutes 30 seconds
1 month ago
Video Episode 64 - Professor Justin Stebbing
Will GLP-1's one day replace our morning coffee? Find out in a special video episode of the Few & Far Between podcast! Host Chris O'Brien welcomes friend of the show, Professor Justin Stebbing. In this new segment, we'll spotlight biotech trends that you need to know about - from T cells to GLP-1 - and identify which innovations are worth the hype. Let's start the podcast!
Few & Far Between: How Biotech Gets Built
Welcome to Few & Far Between! Chris O'Brien, CEO of Biorasi, is your host for fascinating conversations - from clinical research and policymakers to biotech innovators and industry leaders.